Genomic aberrations associated with erlotinib resistance in non-small cell lung cancer cells
M Serizawa, T Takahashi, N Yamamoto… - Anticancer …, 2013 - ar.iiarjournals.org
Background/Aim: Mechanisms of resistance to epidermal growth factor receptor (EGFR)-
tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) are not fully …
tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) are not fully …
Genetic profiling of non‐small cell lung cancer at development of resistance to first‐or second‐generation EGFR‐TKIs by CAPP‐Seq analysis of circulating tumor DNA
K Otsubo, K Sakai, M Takeshita, D Harada… - The …, 2019 - academic.oup.com
Patients with non‐small cell lung cancer (NSCLC) treated with epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors (TKIs) eventually acquire resistance to these …
receptor (EGFR) tyrosine kinase inhibitors (TKIs) eventually acquire resistance to these …
Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
J Wang, B Wang, H Chu, Y Yao - OncoTargets and therapy, 2016 - Taylor & Francis
Identifying activating EGFR mutations is a useful predictive strategy that helps select a
population of advanced non-small-cell lung cancer (NSCLC) patients for treatment with …
population of advanced non-small-cell lung cancer (NSCLC) patients for treatment with …
Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and …
M Narita, E Shimura, A Nagasawa, T Aiuchi, Y Suda… - PLoS …, 2017 - journals.plos.org
Background The EGFR tyrosine kinase inhibitor gefitinib is used in therapy for non-small-cell
lung cancer (NSCLC). However, its application is limited by resistance-accelerated disease …
lung cancer (NSCLC). However, its application is limited by resistance-accelerated disease …
LncRNAs LCETRL3 and LCETRL4 at chromosome 4q12 diminish EGFR-TKIs efficiency in NSCLC through stabilizing TDP43 and EIF2S1
Y Li, Y Shen, M Xie, B Wang, T Wang, J Zeng… - … and Targeted Therapy, 2022 - nature.com
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are effective
targeted therapy drugs for advanced non-small cell lung cancer (NSCLC) patients carrying …
targeted therapy drugs for advanced non-small cell lung cancer (NSCLC) patients carrying …
[HTML][HTML] Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR …
Y Bai, X Liu, L Zheng, S Wang, J Zhang, S Xiong… - Neoplasia, 2023 - Elsevier
Common sensitizing mutations in epidermal growth factor receptor (cEGFR), including exon
19 deletions (19-Del) and exon 21 L858R substitution, are associated with high sensitivity to …
19 deletions (19-Del) and exon 21 L858R substitution, are associated with high sensitivity to …
LncRNA APCDD1L-AS1 induces icotinib resistance by inhibition of EGFR autophagic degradation via the miR-1322/miR-1972/miR-324-3p-SIRT5 axis in lung …
J Wu, C Zheng, Y Wang, Z Yang, C Li, W Fang, Y Jin… - Biomarker …, 2021 - Springer
Background Epidermal growth factor receptor-tyrosinase kinase inhibitor (EGFR-TKI)
resistance is the major obstacle in the treatment of lung adenocarcinoma (LUAD) patients …
resistance is the major obstacle in the treatment of lung adenocarcinoma (LUAD) patients …
Mechanism of resistance and novel targets mediating resistance to EGFR and c-Met tyrosine kinase inhibitors in non-small cell lung cancer
Tyrosine kinase inhibitors (TKIs) against EGFR and c-Met are initially effective when
administered individually or in combination to non-small cell lung cancer (NSCLC) patients …
administered individually or in combination to non-small cell lung cancer (NSCLC) patients …
[HTML][HTML] Analysis of lncRNA, miRNA and mRNA-associated ceRNA networks and identification of potential drug targets for drug-resistant non-small cell lung cancer
X Kong, S Hu, Y Yuan, Y Du, Z Zhu, Z Song, S Lu… - Journal of …, 2020 - ncbi.nlm.nih.gov
Background: Drug resistance to chemotherapeutic drugs or targeted medicines is an
obstacle encountered in the treatment of non-small-cell lung cancer (NSCLC). However, the …
obstacle encountered in the treatment of non-small-cell lung cancer (NSCLC). However, the …
Comprehensive characterization and clinical impact of concomitant genomic alterations in EGFR-mutant NSCLCs treated with EGFR kinase inhibitors
Y Cheng, L Ma, Y Liu, J Zhu, Y Xin, X Liu, Y Wang… - Lung cancer, 2020 - Elsevier
Objectives Although the majority of epidermal growth factor receptor (EGFR)-mutant non-
small cell lung cancer (NSCLC) patients respond to EGFR tyrosine kinase inhibitors (TKIs) …
small cell lung cancer (NSCLC) patients respond to EGFR tyrosine kinase inhibitors (TKIs) …